Kezar Life Sciences, Inc.

NASDAQ:KZR

6.64 (USD) • At close December 27, 2024
Bedrijfsnaam Kezar Life Sciences, Inc.
Symbool KZR
Munteenheid USD
Prijs 6.64
Beurswaarde 48,446,901
Dividendpercentage 0%
52-weken bereik 5.2 - 11.4
Industrie Biotechnology
Sector Healthcare
CEO Mr. John Franklin Fowler
Website https://www.kezarlifesciences.com

An error occurred while fetching data.

Over Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials

Vergelijkbare Aandelen

Utah Medical Products, Inc. logo

Utah Medical Products, Inc.

UTMD

61.89 USD

Icosavax, Inc. logo

Icosavax, Inc.

ICVX

15.31 USD

Aerovate Therapeutics, Inc. logo

Aerovate Therapeutics, Inc.

AVTE

2.67 USD

Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc.

MRSN

1.5 USD

Compass Therapeutics, Inc. logo

Compass Therapeutics, Inc.

CMPX

1.46 USD

Theseus Pharmaceuticals, Inc. logo

Theseus Pharmaceuticals, Inc.

THRX

4.065 USD

InterCure Ltd. logo

InterCure Ltd.

INCR

1.06 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)